The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool

13Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: This research aims to evaluate the predictive performance of a published allopurinol dosing tool. Methods: Allopurinol dose predictions were compared to the actual dose required to achieve serum urate (SU) <0.36 mmol l −1 using mean prediction error. The influence of patient factors on dose predictions was explored using multilinear regression. Results: Allopurinol doses were overpredicted by the dosing tool; however, this was minimal in patients without diuretic therapy (MPE 63 mg day −1 , 95% CI 40–87) compared to those receiving diuretics (MPE 295 mg day −1 , 95% CI 260–330, P < 0.0001). ABCG2 genotype (rs2231142, G>T) had an important impact on the dose predictions (MPE 201, 107, 15 mg day −1 for GG, GT and TT, respectively, P < 0.0001). Diuretic use and ABCG2 genotype explained 53% of the variability in prediction error (R 2  = 0.53, P = 0.0004). Conclusions: The dosing tool produced acceptable maintenance dose predictions for patients not taking diuretics. Inclusion of ABCG2 genotype and a revised adjustment for diuretics would further improve the performance of the dosing tool.

Cite

CITATION STYLE

APA

Wright, D. F. B., Dalbeth, N., Phipps-Green, A. J., Merriman, T. R., Barclay, M. L., Drake, J., … Stamp, L. K. (2018). The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. British Journal of Clinical Pharmacology, 84(5), 937–943. https://doi.org/10.1111/bcp.13516

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free